1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • When a cancer patient tests positive for Covid-19
    Miscellaneous

    Majeed, J.; Garcia, J.; Holland, J.; Daly, B.; Robson, M. E.; Reidy-Lagunes, D.
    Harvard Business Review (2021)

    Fulltext@MSK | Save
  • Clarity plus confidence: Leveraging eConsent to assess participant agency in the consent process
    Meeting Abstract

    O'Shea, M. R.; Buckley, M.; Wang, J.; Galle, J.; Lin, M.; Koch, M.; Lengfellner, J.; Cambria, R.; Rodavitch, A.; Houston, C.; more...
    Journal of Empirical Research on Human Research Ethics (2021)

    Fulltext@MSK | Save
  • Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
    Meeting Abstract

    Tempero, M.; O'Reilly, E.; Van Cutsem, E.; Berlin, J.; Philip, P.; Goldstein, D.; Tabernero, J.; Borad, M.; Bachet, J.; Parner, V.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
    Meeting Abstract

    Janjigian, Y.; Kawazoe, A.; Weber, P.; Luo, S.; Lonardi, S.; Kolesnik, O.; Barajas, O.; Bai, Y.; Shen, L.; Tang, Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Response to total neoadjuvant therapy and survival in patients with early onset locally advanced rectal cancer
    Meeting Abstract

    Lumish, M.; Do, E.; Gonen, M.; Yaeger, R.; Weiser, M.; Cercek, A.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Meeting Abstract

    Van Cutsem, E.; Taieb, J.; Yaeger, R.; Yoshino, T.; Maiello, E.; Elez, E.; Dekervel, J.; Ross, P.; Ruiz Casado, A.; Graham, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
    Meeting Abstract

    André, T.; Shiu, K.; Kim, T.; Jensen, B.; Jensen, L.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Alcaide García, J.; Gibbs, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Effect of prior bevacizumab treatment in BRAF V600Emutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC
    Meeting Abstract

    Aderka, D.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Golden, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
    Meeting Abstract

    Ducreux, M.; Abou-Alfa, G.; Ren, Z.; Edeline, J.; Li, Z.; Assenat, E.; Rimassa, L.; Blanc, J.; Ross, P.; Fang, W.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save